Phi-Former: A Pairwise Hierarchical Approach for Compound-Protein Interactions Prediction
This work addresses a critical bottleneck in drug discovery for pharmaceutical research, offering an incremental improvement over existing deep learning methods by integrating motif-level interactions.
The paper tackles the problem of predicting compound-protein interactions (CPIs) in drug discovery by proposing Phi-former, a pairwise hierarchical method that incorporates molecular motifs to better align with biological recognition, achieving superior performance on CPI-related tasks.
Drug discovery remains time-consuming, labor-intensive, and expensive, often requiring years and substantial investment per drug candidate. Predicting compound-protein interactions (CPIs) is a critical component in this process, enabling the identification of molecular interactions between drug candidates and target proteins. Recent deep learning methods have successfully modeled CPIs at the atomic level, achieving improved efficiency and accuracy over traditional energy-based approaches. However, these models do not always align with chemical realities, as molecular fragments (motifs or functional groups) typically serve as the primary units of biological recognition and binding. In this paper, we propose Phi-former, a pairwise hierarchical interaction representation learning method that addresses this gap by incorporating the biological role of motifs in CPIs. Phi-former represents compounds and proteins hierarchically and employs a pairwise pre-training framework to model interactions systematically across atom-atom, motif-motif, and atom-motif levels, reflecting how biological systems recognize molecular partners. We design intra-level and inter-level learning pipelines that make different interaction levels mutually beneficial. Experimental results demonstrate that Phi-former achieves superior performance on CPI-related tasks. A case study shows that our method accurately identifies specific atoms or motifs activated in CPIs, providing interpretable model explanations. These insights may guide rational drug design and support precision medicine applications.